It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Otitis media (OM) is one of the most globally pervasive pediatric conditions. Translocation of nasopharynx-resident opportunistic pathogens like nontypeable Haemophilus influenzae (NTHi) assimilates into polymicrobial middle ear biofilms, which promote OM pathogenesis and substantially diminish antibiotic efficacy. Oral or tympanostomy tube (TT)-delivered antibiotics remain the standard of care (SOC) despite consequences including secondary infection, dysbiosis, and antimicrobial resistance. Monoclonal antibodies (mAb) against two biofilm-associated structural proteins, NTHi-specific type IV pilus PilA (anti-rsPilA) and protective tip-region epitopes of NTHi integration host factor (anti-tip-chimer), were previously shown to disrupt biofilms and restore antibiotic sensitivity in vitro. However, the additional criterion for clinical relevance includes the absence of consequential microbiome alterations. Here, nine chinchilla cohorts (n = 3/cohort) without disease were established to evaluate whether TT delivery of mAbs disrupted nasopharyngeal or fecal microbiomes relative to SOC-OM antibiotics. Cohort treatments included a 7d regimen of oral amoxicillin-clavulanate (AC) or 2d regimen of TT-delivered mAb, AC, Trimethoprim-sulfamethoxazole (TS), ofloxacin, or saline. Fecal and nasopharyngeal lavage (NPL) samples were collected before and several days post treatment (DPT) for 16S sequencing. While antibiotic-treated cohorts displayed beta-diversity shifts (PERMANOVA, P < 0.05) and reductions in alpha diversity (q < 0.20) relative to baseline, mAb antibodies failed to affect diversity, indicating maintenance of a eubiotic state. Taxonomic and longitudinal analyses showed blooms in opportunistic pathogens (ANCOM) and greater magnitudes of compositional change (P < 0.05) following broad-spectrum antibiotic but not mAb treatments. Collectively, results showed broad-spectrum antibiotics induced significant fecal and nasopharyngeal microbiome disruption regardless of delivery route. Excitingly, biofilm-targeting antibodies had little effect on fecal and nasopharyngeal microbiomes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Abigail Wexner Research Institute at Nationwide Children’s Hospital, Center for Microbial Pathogenesis, Columbus, USA (GRID:grid.240344.5) (ISNI:0000 0004 0392 3476)
2 Department of Otolaryngology at Nationwide Children’s Hospital, Columbus, USA (GRID:grid.240344.5) (ISNI:0000 0004 0392 3476); The Ohio State University, Wexner Medical Center, Department of Pediatrics, Columbus, USA (GRID:grid.412332.5) (ISNI:0000 0001 1545 0811)
3 Abigail Wexner Research Institute at Nationwide Children’s Hospital, Center for Microbial Pathogenesis, Columbus, USA (GRID:grid.240344.5) (ISNI:0000 0004 0392 3476); The Ohio State University, Wexner Medical Center, Department of Pediatrics, Columbus, USA (GRID:grid.412332.5) (ISNI:0000 0001 1545 0811); Abigail Wexner Research Institute at Nationwide Children’s Hospital, Oral and Gastrointestinal Microbiology Research Affinity Group, Columbus, USA (GRID:grid.240344.5) (ISNI:0000 0004 0392 3476)
4 Abigail Wexner Research Institute at Nationwide Children’s Hospital, Center for Microbial Pathogenesis, Columbus, USA (GRID:grid.240344.5) (ISNI:0000 0004 0392 3476); The Ohio State University, Wexner Medical Center, Department of Pediatrics, Columbus, USA (GRID:grid.412332.5) (ISNI:0000 0001 1545 0811)